Wednesday, July 8, 2026

Patent intelligence · US

US 9138453

Nutrient combinations for affecting an aging process

granted A61KA61K31/05A61K31/09A61K31/122
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 9
Applicant portfolio 27
Patent details — US 9138453
Jurisdiction
US
Status
granted
Grant date
Sep 22, 2015
Expiration
Sep 17, 2035
Claims
6
CPC classes
A61K, A61K31/05, A61K31/09, A61K31/122
View on Google Patents ↗

Quick answer

US 9138453 (Nutrient combinations for affecting an aging process) is held by BioMarker Pharmaceuticals, Inc.. Status: granted. Granted Sep 22, 2015. Expires Sep 17, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
6
CPC classes
A61K, A61K31/05, A61K31/09, A61K31/122, A61K31/205, A61K31/221

More from BioMarker Pharmaceuticals, Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 12077601

    Antibodies to ubiquitin C-terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP) and related methods

    BANYAN BIOMARKERS, INC. · Expires Aug 29, 2044

    granted
  2. US 11885817

    Biomarkers and methods for detection of seizures and epilepsy

    Cognizance Biomarkers, LLC · Expires Jan 25, 2044

    granted
  3. US 11692030

    Biomarkers and methods for detection of seizures and epilepsy

    Cognizance Biomarkers, LLC · Expires Jun 29, 2043

    granted
  4. US 11598782

    Biomarkers and methods for detection of seizures and epilepsy

    Cognizance Biomarkers, LLC · Expires Mar 2, 2043

    granted
  5. US 11447500

    Thienopyridine derivatives and pharmaceutical composition comprising same

    Wellmarker Bio Co., LTD. · Expires Sep 15, 2042

    granted
  6. US 11186873

    Combination method for treating cancer by targeting immunoglobulin superfamily member 1 (IGSF1) and mesenchymal-epithelial transition factor (MET)

    Wellmarker Bio Co., LTD. · Expires Nov 25, 2041

    granted
  7. US 11078298

    Antibodies to ubiquitin C-terminal hydrolase L1 (UCH-L1) and glial fibrillary acidic protein (GFAP) and related methods

    BANYAN BIOMARKERS, INC. · Expires Jul 29, 2041

    granted
  8. US 11008622

    Biomarker for predicting sensitivity to EGFR-targeting agent, and use thereof

    Wellmarker Bio Co., LTD. · Expires May 13, 2041

    granted

Frequently asked questions

What is US patent 9138453?

US 9138453 (Nutrient combinations for affecting an aging process) is held by BioMarker Pharmaceuticals, Inc.. Status: granted. Granted Sep 22, 2015. Expires Sep 17, 2035 (9 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 9138453?

BioMarker Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 27 pharmaceutical patents for this assignee.

When does US 9138453 expire?

Our index shows an expiration date of Sep 17, 2035 (9 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.